Few studies on the risk of incident major adverse cardiac and cerebrovascular events in presarcopenic and sarcopenic patients have been reported, with contradictory results [1].
The objective was to assess the association between presarcopenia and sarcopenia, and higher risk of major adverse cardiac and cerebrovascular events.
It was a retrospective analysis of the UK Biobank prospective cohort, using data collected between 2006 and 2021. Community-dwelling Caucasian participants aged 37 to 73 years were included if values for Handgrip Strength and Skeletal Muscle Index were available, and if no history of a major adverse cardiac and cerebrovascular event was reported. Exposure was assessed using the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria [2]. Muscle strength was measured using Handgrip Strength, and muscle mass using the Skeletal Muscle Index (from bioimpedance data). Presarcopenia was defined as low Handgrip Strength with normal Skeletal Muscle Index, whereas sarcopenia was defined as low Handgrip Strength with low Skeletal Muscle Index. Participants with presarcopenia and sarcopenia were merged to form a single group (PreSarc) and were compared against a group of non-sarcopenic participants (NonSarc). To determine whether sarcopenia and/or presarcopenia were predictors of major adverse cardiac and cerebrovascular events (composite events: acute myocardial infarction, angina pectoris, ischemic or hemorrhagic stroke, and transient ischemic attack, whether fatal or non-fatal).
A total of 406,411 participants (women: 55.7%; median age: 58.0 (IQR: [50.0; 63.0]) years) were included. At baseline, 18,612 participants (4.6%) were allocated to the PreSarc group. Over a median follow-up of 12.1 years (IQR: [11.4; 12.8]), 28,300 participants (7.0%) were diagnosed with at least one event. Compared to NonSarc, PreSarc was significantly associated with a higher risk of major adverse cardiac and cerebrovascular events (fully adjusted HR=1.25, 95%CI=[1.20; 1.31]). When presarcopenia and sarcopenia were considered independently, they were still associated with a higher risk of all major adverse cardiac and cerebrovascular events (fully adjusted HR=1.24, 95%CI=[1.18; 1.30]) and HR=1.58, 95%CI=[1.31; 1.90], respectively).
In a community-dwelling population, the risk of major adverse cardiac and cerebrovascular events was higher in both presarcopenic and sarcopenic participants.
[1]Beaudart C, Zaaria M, Pasleau F, Reginster J-Y, Bruyère O. Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis. PLOS ONE 2017;12:e0169548. https://doi.org/10.1371/journal.pone.0169548.
[2]Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16–31. https://doi.org/10.1093/ageing/afy169.
NIL.
None Declared....

POS0952 ASSOCIATION BETWEEN SARCOPENIA AND RISK OF MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN A POPULATION FROM THE UK BIOBANK DATABASE

10.1136/annrheumdis-2023-eular.276